Wall Street analysts predict that Alpine Immune Sciences Inc (NASDAQ:ALPN) will post ($0.23) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Alpine Immune Sciences’ earnings, with estimates ranging from ($0.33) to ($0.10). Alpine Immune Sciences posted earnings per share of ($0.64) during the same quarter last year, which indicates a positive year over year growth rate of 64.1%. The business is expected to report its next earnings results on Tuesday, August 11th.
On average, analysts expect that Alpine Immune Sciences will report full year earnings of ($0.04) per share for the current financial year, with EPS estimates ranging from ($0.76) to $1.71. For the next financial year, analysts expect that the company will report earnings of ($0.23) per share, with EPS estimates ranging from ($0.94) to $0.37. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Alpine Immune Sciences.
Alpine Immune Sciences (NASDAQ:ALPN) last posted its quarterly earnings results on Thursday, May 14th. The biotechnology company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.17. The firm had revenue of $1.09 million during the quarter, compared to analysts’ expectations of $0.38 million. Alpine Immune Sciences had a negative return on equity of 104.04% and a negative net margin of 1,236.45%.
A number of equities analysts recently commented on the company. Zacks Investment Research upgraded Alpine Immune Sciences from a “hold” rating to a “buy” rating and set a $3.75 price target for the company in a report on Thursday, May 21st. Wedbush lifted their price target on Alpine Immune Sciences from $10.00 to $22.00 and gave the stock an “outperform” rating in a report on Friday, June 19th. Piper Sandler lifted their price target on Alpine Immune Sciences from $8.00 to $21.00 in a report on Friday, June 19th. Oppenheimer reiterated a “buy” rating and set a $12.00 price target on shares of Alpine Immune Sciences in a report on Monday, June 8th. Finally, LADENBURG THALM/SH SH reiterated a “buy” rating and set a $17.00 price target on shares of Alpine Immune Sciences in a report on Tuesday, May 26th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $13.96.
A hedge fund recently raised its stake in Alpine Immune Sciences stock. Renaissance Technologies LLC raised its position in shares of Alpine Immune Sciences Inc (NASDAQ:ALPN) by 13.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 127,810 shares of the biotechnology company’s stock after purchasing an additional 15,449 shares during the period. Renaissance Technologies LLC owned approximately 0.69% of Alpine Immune Sciences worth $491,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 43.87% of the company’s stock.
Shares of NASDAQ ALPN traded down $0.33 during mid-day trading on Tuesday, hitting $8.97. The company had a trading volume of 3,007 shares, compared to its average volume of 2,497,047. The company has a market capitalization of $182.16 million, a PE ratio of -4.78 and a beta of 1.47. The firm has a 50-day simple moving average of $7.10 and a two-hundred day simple moving average of $4.14. The company has a current ratio of 7.46, a quick ratio of 7.46 and a debt-to-equity ratio of 0.80. Alpine Immune Sciences has a one year low of $2.05 and a one year high of $15.00.
About Alpine Immune Sciences
Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202, a programmed cell death protein ligand 1 (PD-L1)/cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antagonist with PD-L1 dependent CD28 costimulation for the treatment of cancer.
Featured Story: What is an economic bubble?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.